Ключові слова
гіпертонічна хвороба
параоксоназа 1
ліпіди
Як цитувати
Анотація
Досліджували зміни в системі перекисного окиснення ліпідів та активності параоксонази 1 у 80 хворих на діабетичну нефропатію (ДН) ІI–IV ст. у порівнянні зі змінами у хворих на гіпертонічну хворобу (ГХ), які склали групу порівняння (15 осіб). Групу контролю склали 10 здорових осіб. Було встановлено, що прогресування ДН супроводжується зниженням активності параоксонази 1, що вказує на погіршення антиоксидантного захисту. Встановлено також, що вік хворого на ДН є ще одним фактором, який негативно впливає на стан перекисних процесів. Дисфункція антиоксидантної системи у хворих на ДН вимагає розробки схем корекції та, скоріше за все, постійного лікування антиоксидантними препаратами.Посилання
Mikhalchishin H.P., Zilova A.V. (2008). Sovremennyye strategii vedeniya patsiyentov s SD 2 tipa: v tsentre vnimaniya – profilaktika serdechno-sosudistykh oslozhneniy [Modern strategies for management of patients with type 2 diabetes: focus on the prevention of cardiovascular complications]. Zdoroviia Ukrainy – Health of Ukraine, № 21–24, pp. 48–49 [in Russian].
Mankovskii B.N. (2008). Terapiia SD 2 tipa: vchera, segodnya, zavtra. Rezul'taty issledovaniya ADVANCE [Therapy of type 2 diabetes: yesterday, today, tomorrow. The results of the ADVANCE]. Zdoroviia Ukrainy – Health of Ukraine,
№ 15–16, pp. 12–13 [in Russian].
Juutilainen A., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. (2005). Type 2 diabetes as a «coronary heart disease equivalent»: an 18-year prospective population-based study in Finnish subjects. Diabetes Care, vol. 28, pp. 2901–2907.
Van Dieren S., Beulens J.W., Kengne A.P., Peelen L.M., Rutten G.E., Woodward M. et al. (2012). Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart, vol. 98, pp. 360–369.
Hanefeld M., Marx N., PfütznerA., Baurecht W., Lübben G., Karagiannis E. et al. (2007). Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein the PIOSTAT study. J. Am. Coll. Cardiol, vol. 49. pp. 290–297.
Ulugahapitiya U., Siyambalapitiya S., Sithole J., Idris I. (2009). Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet. Med, vol. 26, pp. 142–148.
Netiazhenko V., Barna O., Solomenchuk T. (2003). Ateroskleroz pry tsukrovomu diabeti II typu: stratehiia likuvannia dyslipidemii [Atherosclerosis in type 2 diabetes mellitus: a strategy for the treatment of dyslipidemia]. Liky Ukraiiny – Medications for Ukraine, № 10, pp. 4–10 [in Ukrainian].
Spesyvtseva V.H., Kakhnovskyi I.M., Mamaieva H.H. (2002). Deyaki metody likuvannia tsukrovoho diabetu i yoho uskladnen [Some methods of treating diabetes mellitus and its complications]. Terapevticheskii arkhiv – Therapeutic archive, № 3, pp. 105–108 [in Ukrainian].
Maliukova N.H. (2004). Vplyvy zakhvoriuvan nyrok na protsesy peroksydnoho okyslennia lipidiv – antyoksydantnoi systemy pry khronichnii sertsevii nedostatnosti [Influences of diseases on the processes of peroxide lipid oxidation – antioxidant system in chronic heart failure]. Urolohiia – Urology, № 4, pp. 30–33 [in Ukrainian].
Pyrih L.A., Dudar I.O., Nikulina H.H. (2001). Perekysne okyslennia lipidiv ta protsesy membrano-stabilizatsii pry hlomerulonefriti u khvorykh riznoho viku [Peroxide lipid oxidation and membrane-stabilization processes in glomerulonephritis in patients of all ages]. Zhurnal AMN Ukrainy – Journal of the Academy of Medical Sciences of Ukraine, № 2, pp. 285–296 [in Ukrainian].
Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. Journal of Clinical Investigation, vol. 101 (8), pp. 1581–1590.
Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M. et al. (1998). Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18 (10), pp. 1617–1624.
Rosenblat M., Volkova N., Ward J., Aviram M. (2011). Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis, vol. 219 (1), pp. 49–56.
Rosenblat M., Volkova N., Roqueta-Rivera M., Nakamura M.T., Aviram M. (2010). Increased macrophage cholesterol biosynthesis and decreased cellular paraoxonase 2 (PON2) expression in Δ6-desaturase knockout (6-DS KO) mice: beneficial effects of arachidonic acid. Atherosclerosis, vol. 210 (2), pp. 414–421.
Efrat M., Aviram M. (2008). Macrophage paraoxonase 1 (PON1) binding sites. Biochemical and Biophysical Research Communications, vol. 376 (1), pp. 105–110.
Mackness M.I., Arrol S., Abbott C., Durrington P.N. (1993). Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, vol. 104 (1–2), pp. 129–135.
MacKness B., MacKness M. (2010). Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Advances in Experimental Medicine and Biology,
vol. 660, pp. 143–151.
Goswami B., Tayal D., Gupta N., Mallika V. (2009). Paraoxonase: a multifaceted biomolecule. Clinica Chimica Acta, vol. 410 (1–2), pp. 1–12.
Gordon S.M., Hofmann S., Askew D.S., Davidson W.S. (2011). High density lipoprotein: it’s not just about lipid transport anymore. Trends in Endocrinology and Metabolism, vol. 22 (1), pp. 9–15. [PMC free article]
Lee J.M., Choudhury R.P. (2010). Atherosclerosis regression and high-density lipoproteins. Expert Review of Cardiovascular Therapy, vol. 8 (9), pp. 1325–1334.
Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M. et al. (2003). Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation, vol. 107 (22), pp. 2775–2779.
Ferretti G., Bacchetti T., Masciangelo S., Nanetti L., Mazzanti L., Silvestrini M.
et al. (2008). Lipid peroxidation in stroke patients. Clinical Chemistry and Laboratory Medicine, vol. 46 (1), pp. 113–117.
Costa L.G., Vitalone A., Cole T.B., Furlong C.E. (2005). Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology, vol. 69 (4), pp. 541–550.
Zakhariia E.A., Detsyk Yu.I. (1989). Laboratornaia diahnostika ishemicheskoi bolezni serdtsa [Laboratory diagnosis of coronary heart disease]. Moscow, p. 73 [in Russian].
Fedorova T.K., Korshunova T.S., Larskaia Ye.T. (1983). Reaktsiia s TBK dlia opredeleniia MDA krovi metodom flyuorimetrii [Reaction with TBA for the determination of MDA of blood by fluorometry] Laboratornoie delo – Laboratory work, № 3, pp. 25–28 [in Russian].
Kochetov T.A. Prakticheskoie posobiie po enzimolohii [Practical manual on enzymology]. Moscow, p. 217 [in Russian].
Severin S.Ye., Solovieva T.A. (eds.) (1989). Praktikum po biokhimii [Workshop on Biochemistry]. Moscow : MGU, pp. 160–161 [in Russian].
Harry W. Eckepson, Joseph Romson, Collette Wyte, Bept N. La Du. (1983). The human serum paraoxonase polymorphism: identification of phenotypes by their response to sails. Am. J. Hum. Genet, vol. 35, pp. 214–227.
Ferré N., Camps J., Prats E., Vilella E., Paul A., Figuera L. et al. (2002). Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clinical Chemistry, vol. 48, pp. 261–268.
Netyazhenko V., Barna O., Solomenchuk T. (2003). Ateroskleroz pry tsukrovomu diabeti II typu: stratehiya likuvannya dyslipidemiy [Atherosclerosis in type 2 diabetes mellitus: the strategy of treatment of dyslipidemia]. Liky Ukraiiny – Medications for Ukraine, № 10, pp. 4–10.
Sirenko Yu.M., Hranich V.M., Radchenko H.D. (2003). Urazhennia orhaniv-mishenei pry arterialnii hipertenzii: profilaktyka, diahnostyka ta likuvannia: Vetod. rekomendatsii [Defeat of target organs in arterial hypertension: prophylaxis, diagnosis and treatment: Methodical recommendations], Kyiv, 42 p.